-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QrSGgf00iGTK37yj4Neh58CK7gLMYidygQ94K7z56YJdrW9ACXCEF/LzrIb3b0/R VSvDyeCt2K5fKd1PSXmEJQ== 0001144204-05-024953.txt : 20050812 0001144204-05-024953.hdr.sgml : 20050812 20050812153422 ACCESSION NUMBER: 0001144204-05-024953 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050630 FILED AS OF DATE: 20050812 DATE AS OF CHANGE: 20050812 EFFECTIVENESS DATE: 20050812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BAKER BROS ADVISORS LLC CENTRAL INDEX KEY: 0001263508 IRS NUMBER: 134093645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10519 FILM NUMBER: 051021415 BUSINESS ADDRESS: STREET 1: 667 MADISON AVENUE STREET 2: 17TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 2125212418 13F-HR 1 v022936_13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: June 30, 2005 Check here if Amendment [ ]; Amendment Number: _____ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Baker Bros. Advisors, LLC -------------------------------------------- Address: 667 Madison Avenue, 17th Floor -------------------------------------------- New York, NY 10021-8029 -------------------------------------------- Form 13F File Number: 28-10519 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Leo Kirby -------------------------------------------- Title: Chief Financial Officer -------------------------------------------- Phone: 212-521-2418 -------------------------------------------- Signature, Place, and Date of Signing: /s/ Leo Kirby New York, N.Y. _____, 2005 - -------------------------- --------------------------- ---------------------- [Signature] [City, State] [Date] Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [_] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: None FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 ----------- Form 13F Information Table Entry Total: 56 ----------- Form 13F Information Table Entry Value: 397,689 ----------- (thousands) List of Other Included Managers: None
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 TITLE OF VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ----------------- ----- ----- -------- ------- --- ---- ---------- -------- ---- ------ ---- Acadia Pharmaceuticals Inc. COM 004225108 3,726 443,608 SH SOLE 443,608 Adolor Corp. COM 00724X102 13,663 1,477,074 SH SOLE 1,477,074 Alexion Pharmaceuticals Inc. COM 015351109 4,935 214,201 SH SOLE 214,201 Allos Therapeutics Inc. COM 019777101 6,207 2,847,418 SH SOLE 2,847,418 Amylin Pharmaceuticals Inc. COM 032346108 41,875 2,000,722 SH SOLE 2,000,722 Anadys Pharmaceuticals Inc. COM 03252Q408 3,609 393,958 SH SOLE 393,958 Arena Pharmaceuticals Inc. COM 040047102 1,147 168,133 SH SOLE 168,133 Array Biopharma Inc. COM 04269X105 2,553 405,174 SH SOLE 405,174 Autoimmune Inc. COM 052776101 23 26,100 SH SOLE 26,100 Barrier Therapeutics Inc. COM 06850R108 1,198 151,046 SH SOLE 151,046 Biocryst Pharmaceuticals Inc. COM 09058V103 11,908 2,344,036 SH SOLE 2,344,036 Corcept Therapeutics Inc. COM 218352102 663 115,100 SH SOLE 115,100 Critical Therapeutics Inc. COM 22674T105 6,855 976,542 SH SOLE 976,542 Cytokinetics Inc. COM 23282W100 821 118,300 SH SOLE 118,300 Dynavax Technologies Corp. COM 268158102 284 59,100 SH SOLE 59,100 GTXI Inc. Del COM 40052B108 2,627 264,259 SH SOLE 264,259 Incyte Corp. COM 45337C102 23,696 3,314,070 SH SOLE 3,314,070 Inhibitex Inc. COM 45719T103 6,648 879,430 SH SOLE 879,430 Insmed Inc. COM 457669208 27 27,076 SH SOLE 27,076 Intermune Inc. COM 45884X103 2,315 177,513 SH SOLE 177,513 Intrabiotics Pharmaceuticals COM 46116T506 3,357 959,271 SH SOLE 959,271 Ligand Pharmaceuticals Inc. CLB 53220K207 962 138,357 SH SOLE 138,357 Martek Bioscience Corp. COM 572901106 2,843 74,900 SH SOLE 74,900 Medarex Inc. COM 583916101 16,287 1,962,305 SH SOLE 1,962,305 Metabasis Therapeutics Inc. COM 59101M105 1,631 517,710 SH SOLE 517,710 Myogen Inc. COM 62856E104 3,338 477,597 SH SOLE 477,597 Nastech Pharmaceutical Inc. COM 631728409 2,875 202,056 SH SOLE 202,056 Neose Technologies Inc. COM 640522108 2,478 786,825 SH SOLE 786,825 Neurocrine Bioscience Inc. COM 64125C109 400 9,500 SH SOLE 9,500 Neurogen Corp. COM 64124E106 36,323 5,325,999 SH SOLE 5,325,999 Nitromed Inc. COM 654798503 1,616 83,074 SH SOLE 83,074 Nuvelo Inc. COM 67072M301 6,867 888,326 SH SOLE 888,326 Pharmacyclics Inc. COM 716933106 3,464 461,288 SH SOLE 461,288 Pozen Inc. COM 73941U102 268 32,400 SH SOLE 32,400 Praecis Pharmaceuticals Inc. COM 739421105 26 50,100 SH SOLE 50,100 Progenics Pharmaceuticals Inc. COM 743187106 522 25,000 SH SOLE 25,000 Seattle Genetics Inc. COM 812578102 6,405 1,194,927 SH SOLE 1,194,927 Senomyx Inc. COM 81724Q107 11,610 703,202 SH SOLE 703,202 Sequenom Inc. COM 817337108 57 48,881 SH SOLE 48,881 Theravance Inc. COM 88338T104 6,985 410,869 SH SOLE 410,869 Trimeris Inc. COM 896263100 35,952 3,602,369 SH SOLE 3,602,369 Vertex Pharmaceuticals Inc. COM 92532F100 8,000 474,798 SH SOLE 474,798 Vicuron Pharmaceuticals Inc. COM 926471103 346 12,400 SH SOLE 12,400 Virologic Inc. COM 92823R201 989 398,619 SH SOLE 398,619 Viropharma Inc. COM 928241108 28,085 4,041,041 SH SOLE 4,041,041 Xcyte Therapies Inc. PFD CV EXCH 98389F408 310 95,500 SH SOLE 95,500 Xenoport Inc. COM 98411C100 2,660 250,000 SH SOLE 250,000 Zymogenetics Inc. COM 98985T109 1,873 106,432 SH SOLE 106,432 Alexion Pharmaceuticals Notes 1.375% 2/01/2012 CONV BONDS 015351AF6 42,377 43,800,000 PRN SOLE 43,800,000 Incyte Genomics Notes 3.5% 2/15/2011 CONV BONDS 45337CAE2 3,475 4,000,000 PRN SOLE 4,000,000 Medarex Inc Notes 2.25% 5/15/2011 CONV BONDS 583916AG6 5,688 6,500,000 PRN SOLE 6,500,000 Oscient Pharmaceuticals Corp Notes 3.5% 4/15/2011 CONV BONDS 68812RAB1 803 1,000,000 PRN SOLE 1,000,000 Regeneron Conv Notes 5.5% 10/17/08 (144A) CONV BONDS 75886FAA5 10,659 12,322,000 PRN SOLE 12,322,000 Regeneron Conv Notes 5.5% 10/17/08 CONV BONDS 75886FAB3 4,325 5,000,000 PRN SOLE 5,000,000 Viropharma Incorporated Notes 6% 3/01/2007 CONV BONDS 928241AC2 5,938 5,975,000 PRN SOLE 5,975,000 Viropharma Incorporated Notes 6% 10/18/2009 CONV BONDS 928241AG3 3,119 1,059,000 PRN SOLE 1,059,000
-----END PRIVACY-ENHANCED MESSAGE-----